Francesco Corazza spent a decade building a wearable device to detect epileptic seizures. The technology worked. But whilst the engineering hurdles had been cleared, the device languished in what he calls 'regulatory limbo' – buried under hundreds of pages of documentation, caught in the grinding machinery of medical device approval processes where even seasoned experts disagree on how to interpret the rules.
That frustration has now become Klaris, a London medtech startup that just closed a £730,000 pre-seed round to automate the regulatory compliance process for medical device manufacturers. The pitch is simple: if 69% of US device submissions are rejected first time round, according to FDA analysis, there's clearly something broken in how companies prepare their paperwork.
The funding comes primarily from Meridian Health Ventures, a specialist investor backed by Guy's and St Thomas' NHS Foundation Trust, King's College Hospital, UCLH, and Cedars-Sinai Medical Center in the US. That's an interesting signal. When the institutional machinery of the NHS itself is backing a startup designed to solve regulatory bottlenecks, you're looking at more than just venture capital spotting an inefficiency – you're seeing the healthcare system acknowledging its own friction points.
When bureaucracy becomes a brake on patient access
What's notable here isn't just the rejection rate, but what it represents in wasted capital and delayed patient outcomes. Every failed submission means months of rework, legal fees, consultant hours, and opportunity cost. For venture-backed medtech companies burning cash to reach commercialisation, each regulatory setback can be existential.
Madhav Mahendra, principal at Meridian Health Ventures, frames it as a structural constraint on the industry. 'Regulatory compliance has become a defining constraint in medtech, with rising MDR and FDA complexity only exacerbating approval bottlenecks,' he said, referencing both US Food and Drug Administration rules and the EU's increasingly stringent Medical Device Regulation regime introduced in 2017.
The European regulatory overhaul, in particular, has created a new layer of complexity. Under the MDR framework, thousands of existing devices have required recertification, and the standards for technical documentation have become markedly more demanding. If Klaris can genuinely compress approval timelines in both jurisdictions, the addressable market isn't small – it's every medical device manufacturer navigating either the FDA or MHRA approval processes.
But the critical question is what 'automating' regulatory compliance actually means in practice. Does Klaris's platform flag potential issues in draft submissions, or does it generate the documentation itself? And crucially, are regulators comfortable accepting AI-authored technical files for devices that will be implanted in patients or used in critical care settings?
From managing paperwork to eliminating it
Corazza's framing is instructive: the industry has spent years building 'better ways to manage that paperwork instead of eliminating it'. That's the wedge. Medical device companies currently rely on expensive regulatory consultants and in-house compliance teams to shepherd submissions through approval. If an AI platform can detect gaps, cross-reference regulations, and produce draft content that meets regulatory standards, it shifts from a cost-saving tool to strategic infrastructure.
Whether that vision holds up depends on execution. The 69% rejection statistic, whilst striking, lacks granularity. Are these rejections driven by minor administrative oversights – a missing signature, an incomplete form – or substantive concerns about clinical evidence and safety data? If it's the former, automation has a clear role. If it's the latter, no amount of AI will substitute for robust clinical trials and proper risk assessment.
What's more interesting is the broader pattern Klaris represents. Legal tech has spent the past five years applying AI to contract review and compliance. Fintech has automated KYC and AML processes that once required armies of analysts. Medtech regulatory approval is arguably more complex than either – it involves interpreting constantly evolving standards, cross-referencing technical specifications with clinical data, and producing documentation that satisfies regulators in multiple jurisdictions.
If Klaris can crack this, it's not just a medtech story. It's evidence that AI is moving beyond pattern recognition and natural language processing into genuine regulatory interpretation – a capability with implications far beyond medical devices.
What happens when the NHS backs a solution to its own bottleneck
The participation of NHS trusts in the funding round raises a strategic question: are they simply limited partner investors in the fund, or are they potential customers? The NHS is both a major procurer of medical devices and notoriously slow at adopting new technology. If Klaris can accelerate the approval process for devices destined for NHS procurement, the institutional backing makes commercial sense.
Additional funding came from Antler, Vento Ventures, Alecla7, and angel investors, giving Klaris a mix of generalist early-stage capital and specialist healthcare backing. For a pre-seed round, that's a reasonably strong syndicate – enough runway to prove the platform works without giving away excessive equity.
The real test will be whether medical device manufacturers adopt the platform at scale, and whether regulators view AI-assisted documentation as legitimate or requiring additional scrutiny. If approval timelines genuinely compress, expect every medtech startup to follow. If regulators push back, this becomes a much harder sell.
Corazza's seizure-detecting wearable may still be working its way through approvals, but his next venture is betting that the paperwork problem can be solved with software. Whether that transforms medtech innovation or simply adds another layer to an already complex process will define how much this £730,000 round was worth.
